This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 1 of 1 for:    "NCT02079636"
Previous Study | Return to List | Next Study

A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)

This study is currently recruiting participants.
See Contacts and Locations
Verified July 2017 by Eli Lilly and Company
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT02079636
First received: March 4, 2014
Last updated: July 5, 2017
Last verified: July 2017
  Purpose
The main purpose of this study is to evaluate the safety and tolerability of abemaciclib in combination with another anti-cancer drug in participants with NSCLC that is advanced or has spread to other parts of the body (stage IV). The study will also investigate how the body processes the combination treatment and how the study drug affects the body. The study will also collect disease-related symptoms and participant-reported pain related to NSCLC.

Condition Intervention Phase
Carcinoma, Non-small Cell Lung Drug: Abemaciclib Drug: Pemetrexed Drug: Gemcitabine Drug: Ramucirumab Drug: LY3023414 Drug: Pembrolizumab Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1b Study of LY2835219 in Combination With Multiple Single Agent Options for Patients With Stage IV NSCLC

Resource links provided by NLM:


Further study details as provided by Eli Lilly and Company:

Primary Outcome Measures:
  • Number of Participants with One or More Drug Related Adverse Events [ Time Frame: Baseline through study completion (15 months) ]

Secondary Outcome Measures:
  • Pharmacokinetics: Maximum Concentration (Cmax) of Abemaciclib, Pemetrexed, Gemcitabine, Ramucirumab, and LY3023414 [ Time Frame: Baseline through study completion (15 months) ]
  • Number of Participants with a Complete or Partial Tumor Response (Overall Response Rate) [ Time Frame: Baseline through study completion (15 months) ]
  • Progression Free Survival Time [ Time Frame: Date of first dose until first documented progression or death (15 months) ]
  • Change from Baseline in MD Anderson Symptom Inventory Scale-Lung Cancer (MDASI-LC) [ Time Frame: Baseline, through study completion (15 months) ]
  • Pharmacokinetics: Area Under the Concentration Curve (AUC) of Abemaciclib, Pemetrexed, Gemcitabine, Ramucirumab, and LY3023414 [ Time Frame: Baseline through study completion (15 months) ]

Estimated Enrollment: 150
Study Start Date: March 2014
Estimated Study Completion Date: June 2018
Estimated Primary Completion Date: June 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Abemaciclib + Pemetrexed
Abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 500 milligrams/square meter (mg/m^2) pemetrexed given intravenously (IV) over approximately 10 minutes on Day 1 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
Drug: Abemaciclib
Administered orally
Other Name: LY2835219
Drug: Pemetrexed
Administered IV
Other Name: Alimta
Experimental: Abemaciclib + Gemcitabine
Abemacicilib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 1250 milligram/square meter (mg/m^2) gemcitabine given intravenously over approximately 30 minutes on Days 1 and 8 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
Drug: Abemaciclib
Administered orally
Other Name: LY2835219
Drug: Gemcitabine
Administered IV
Other Name: Gemzar
Experimental: Abemaciclib + Ramucirumab
Abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 10 milligram/kilogram (mg/kg) ramucirumab given intravenously over approximately 60 minutes on Day 1 or 8 to 10 milligram/kilogram (mg/kg) ramucirumab given intravenously over approximately 60 minutes on Days 1 and 8 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
Drug: Abemaciclib
Administered orally
Other Name: LY2835219
Drug: Ramucirumab
Administered IV
Other Name: Cyramza
Experimental: Abemaciclib + LY3023414
Abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 100, 150, or 200mg LY3023414 given orally every 12 hours on Days 1 through 21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
Drug: Abemaciclib
Administered orally
Other Name: LY2835219
Drug: LY3023414
Administered orally
Experimental: Abemaciclib + Pembrolizumab
Abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 200 mg pembrolizumab given intravenously over approximately 30 minutes on day 1 of a 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
Drug: Abemaciclib
Administered orally
Other Name: LY2835219
Drug: Pembrolizumab
Administered IV

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • For all Parts: The participant must have stage IV non-small cell lung cancer (NSCLC).
  • For Part A (abemaciclib + pemetrexed): Non-squamous subtypes only. The participant must have received at least one but no more than three prior therapies for advanced/metastatic NSCLC.
  • For Part B (abemaciclib + gemcitabine): Any subtype. The participant must have received at least one but not more than three prior therapies for advanced/metastatic NSCLC.
  • For Part C (abemaciclib + ramucirumab): Any subtype. The participant must have received at least two but not more than three prior therapies for advanced/metastatic NSCLC.
  • For Part D (abemaciclib + LY3023414): Any subtype. The participant must have received at least two, but not more than three prior therapies for advanced/metastatic NSCLC. The participant must not have received prior treatment with any phosphoinositide 3-kinase (PI3K) or mammalian target of rapamycin (mTOR) inhibitor.
  • For Part E (abemaciclib + pembrolizumab): Any subtype. The participant must have received at least one but no more than three prior therapies for advanced/metastatic NSCLC.
  • Have either measureable or nonmeasurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST v1.1).
  • Have adequate organ function including:

    • Hematologic: Absolute neutrophil count (ANC) 1.5 x 109/liter (L), platelets 100 x 109/L, and hemoglobin 8 gram/deciliter (g/dL).
    • Hepatic: Bilirubin 1.5 times upper limits of normal (ULN), alanine aminotransferase (ALT) and aspartate transaminase (AST) 3.0 times ULN. For participants with tumor involvement of the liver, AST and ALT equaling ≤5.0 times ULN are acceptable. Alkaline phosphatase ≤5.0 times ULN for participants with tumor involvement of the bone is acceptable.
    • Renal: Serum creatinine 1.5 times ULN.
  • Have a performance status ≤1 on the Eastern Cooperative Oncology Group (ECOG) scale.
  • Have discontinued all previous therapies for cancer (including chemotherapy, radiotherapy, immunotherapy, and investigational therapy) for at least 21 days for myelosuppressive agents or 14 days for nonmyelosuppressive agents prior to receiving study drug, and recovered from the acute effects of therapy (treatment related toxicity resolved to baseline) except for residual alopecia.
  • Male and female participants of reproductive potential must agree to use medically approved contraceptive precautions during the trial and 3 to 4 months (as appropriate) following last dose of study drug.
  • Have an estimated life expectancy of ≥12 weeks.
  • Are able to swallow oral medications.

Exclusion Criteria:

  • Have a personal history of any of the following conditions: presyncope or syncope of either unexplained or cardiovascular etiology, ventricular arrhythmia (including but not limited to ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest. Exception: Participants with controlled atrial fibrillation for >30 days prior to study treatment are eligible.
  • Parts A, B, D and E: Have central nervous system (CNS) metastasis with development of associated neurological changes 14 days prior to receiving study drug.
  • Have a history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix or breast), unless in complete remission with no therapy for a minimum of 3 years.
  • Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 3 to 4 months after the last dose of trial treatment (as appropriate).
  • Have active bacterial, fungal, and/or known viral infection (for example, human immunodeficiency virus [HIV] antibodies, hepatitis B surface antigen [HBSAg], or hepatitis C antibodies). Screening is not required for enrollment.
  • Parts A, B, C, and E: Have QTc interval of > 470 millisecond (msec) on screening electrocardiogram (ECG). Part D participants have QTc interval of >450msec on screening ECG.

Additional Exclusion Criteria For Part C

  • History or evidence of cardiovascular risk including any of the following:

    • History of acute coronary syndromes (including myocardial infarction and angina), coronary angioplasty, or stenting within 6 months prior to enrollment.
    • History or evidence of current ≥Class II congestive heart failure as defined by New York Heart Association.
    • Treatment refractory hypertension defined as a blood pressure of systolic >140 millimeter of mercury (mmHg) and/or diastolic >90 mmHg which cannot be controlled by antihypertensive therapy.
    • Participants with intracardiac defibrillators.
  • History or evidence of CNS disease. Radiographic screening of all participants without history of CNS metastasis is required.
  • Radiographically documented evidence of major vessel invasion or encasement by cancer.
  • Uncontrolled thromboembolic or hemorrhagic disorders.
  • Participants receiving daily treatment with aspirin >325mg/day or other known inhibitors of platelet function.
  • History of gross hemoptysis within 2 months of study entry.
  • Evidence of nonhealing wounds, ulcers, or bone fractures within 28 days prior to study entry.
  • Undergone major surgery within 28 days prior to first dose of study drug or have subcutaneous venous access device placement within 7 days prior to first dose.

Additional Exclusion Criteria For Part D

  • Have insulin-dependent diabetes mellitus or a history of gestational diabetes mellitus.
  • Participants with a type 2 diabetes mellitus are eligible if adequate control of blood glucose level is obtained by oral anti-diabetic agents as documented by hemoglobin A1c (HbA1c) <7%.
  • History or evidence of cardiovascular risk including any of the following -- History of acute coronary syndromes (including myocardial infarction and angina), coronary angioplasty, or stenting within 6 months prior to enrollment.

Additional Exclusion Criteria for Part E

  • Received prior monoclonal antibody (mAb) within 4 weeks prior to study.
  • Has active autoimmune disease that has required treatment in the past 2 years.
  • Has history of interstitial lung disease or pneumonitis.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02079636

Contacts
Contact: There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559

Locations
United States, Arkansas
Highlands Oncology Group Recruiting
Fayetteville, Arkansas, United States, 72703
Contact    479-872-8130      
Principal Investigator: Eric Schaefer         
United States, California
UCLA Department of Medicine-Hematology/Oncology Recruiting
Los Angeles, California, United States, 90095
Contact    310-633-8400      
Principal Investigator: Jonathan Goldman         
University of California, Davis - Health Systems Recruiting
Sacramento, California, United States, 95817
Contact    916-734-3735      
Principal Investigator: Karen Kelly         
United States, Indiana
Indiana Cancer Pavilion Recruiting
Indianapolis, Indiana, United States, 46202
Contact    317-274-4505      
Principal Investigator: Shadia Jalal         
United States, New Jersey
Hackensack University Medical Center Recruiting
Hackensack, New Jersey, United States, 07601
Contact    551-996-5830      
Principal Investigator: Martin Gutierrez         
United States, New Mexico
University of New Mexico Cancer Center Recruiting
Albuquerque, New Mexico, United States, 87102
Contact    505-925-0403      
Principal Investigator: Emrullah Yilmaz         
United States, North Carolina
Carolinas Medical Center Recruiting
Charlotte, North Carolina, United States, 28204
Contact    980-442-3105      
Principal Investigator: Edward Kim         
United States, Tennessee
The West Clinic Recruiting
Germantown, Tennessee, United States, 38138
Contact    901-683-0055      
Principal Investigator: Daruka Mahadevan         
Spain
Hospital Universitario Ramon y Cajal Recruiting
Madrid, Spain, 28034
Contact    34913368263      
Principal Investigator: Pilar Garrido López         
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Recruiting
Majadahonda, Spain, 28222
Contact: Eli Lilly and Company         
Hospital Virgen del Rocío Recruiting
Sevilla, Spain, 41013
Contact    0034955012000      
Principal Investigator: Miriam Alonso Garcia         
Sponsors and Collaborators
Eli Lilly and Company
Merck Sharp & Dohme Corp.
Investigators
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
  More Information

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT02079636     History of Changes
Other Study ID Numbers: 15266
I3Y-MC-JPBJ ( Other Identifier: Eli Lilly and Company )
2013-004648-41 ( EudraCT Number )
KEYNOTE-238 ( Other Identifier: Merck )
Study First Received: March 4, 2014
Last Updated: July 5, 2017

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Gemcitabine
Pemetrexed
Pembrolizumab
Ramucirumab
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Folic Acid Antagonists
Nucleic Acid Synthesis Inhibitors

ClinicalTrials.gov processed this record on September 19, 2017